We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
With U.S.-China trade relations turning sour, it’s been a generally good idea to bail out of stocks with China exposure. But not all stocks are made the same, a case in point being Alibaba (BABA - Free Report) .
Here are some solid reasons you should be buying this stock-
1. China’s leading ecommerce company has a solid track record. Between fiscal years 2016 to 2019 (ending March), revenue grew more than 254% while earnings grew around 138%. In the just reported quarter, revenue grew 21.7% while earnings before non-recurring items grew 63.0%. Moreover, it guided to a revenue increase of 33% in fiscal year 2020 to RMB 500 billion.
2. The leading Chinese ecommerce company by far has 58% share in the country as of June 2018 (Statista) with the second player JD.com JD remaining far behind at 16%. Since Alibaba primarily operates in China, i.e., its business activity is primarily in China, it has Chinese government support. The Chinese population is large and Chinese disposable income continues to increase, making it a good market for sellers.
3. Alibaba caters to practically every ecommerce need like food ordering, film and TV, and a ubiquitous mobile and online payments platform (Alipay). The company also has a huge cloud infrastructure business that is even more dominant in China than Amazon (AMZN - Free Report) is in the U.S.
Alibaba’s relatively later start has not been a problem for the company because of the government’s protectionism, something that the company can expect to continue in the future. Since the Chinese market is far larger than the U.S. and Chinese competition in the space is even further behind than Microsoft (MSFT - Free Report) and Alphabet (GOOGL - Free Report) , Alibaba has a solid growth path waiting for it.
4. Moody’s has a positive view of the company’s strengths. SVP Lina Choi says, "We expect that Alibaba's strong revenue growth and robust operating cash flow generation will continue to support its investment needs, and a credit profile appropriate for its A1 ratings."
5. The trade war, especially the last round of Trump tariffs has sent its shares crashing, so that they are now at quite an attractive valuation. As a result, the P/E based on forward 12 months earnings of 28.88X is well below the median value of 33.58 over the past year. It’s also better than the industry’s 38.37X.
6. Interestingly, Alibaba is reportedly considering a Hong Kong listing to raise $20 billion according to people with confidential knowledge of the matter. The company needs to maintain liquidity and increase investment in technology is all we are getting from the read. But considering the U.S. government’s strong stand with respect to Huawei and Hong Kong recently relaxing its listing requirements, Alibaba may be looking to raise funds that can help it pull out of the U.S.
Market watcher and former Trump chief adviser Steve Bannon’s recent comment in the South China Morning Post reads: "The next move we make is to cut off all the IPOs, unwind all the pension funds and insurance companies in the U.S. that provide capital to the Chinese Communist Party." If this is true, it could be an opportunity to make some money.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Why You Should Buy Alibaba Now
With U.S.-China trade relations turning sour, it’s been a generally good idea to bail out of stocks with China exposure. But not all stocks are made the same, a case in point being Alibaba (BABA - Free Report) .
Here are some solid reasons you should be buying this stock-
1. China’s leading ecommerce company has a solid track record. Between fiscal years 2016 to 2019 (ending March), revenue grew more than 254% while earnings grew around 138%. In the just reported quarter, revenue grew 21.7% while earnings before non-recurring items grew 63.0%. Moreover, it guided to a revenue increase of 33% in fiscal year 2020 to RMB 500 billion.
2. The leading Chinese ecommerce company by far has 58% share in the country as of June 2018 (Statista) with the second player JD.com JD remaining far behind at 16%. Since Alibaba primarily operates in China, i.e., its business activity is primarily in China, it has Chinese government support. The Chinese population is large and Chinese disposable income continues to increase, making it a good market for sellers.
3. Alibaba caters to practically every ecommerce need like food ordering, film and TV, and a ubiquitous mobile and online payments platform (Alipay). The company also has a huge cloud infrastructure business that is even more dominant in China than Amazon (AMZN - Free Report) is in the U.S.
Alibaba’s relatively later start has not been a problem for the company because of the government’s protectionism, something that the company can expect to continue in the future. Since the Chinese market is far larger than the U.S. and Chinese competition in the space is even further behind than Microsoft (MSFT - Free Report) and Alphabet (GOOGL - Free Report) , Alibaba has a solid growth path waiting for it.
4. Moody’s has a positive view of the company’s strengths. SVP Lina Choi says, "We expect that Alibaba's strong revenue growth and robust operating cash flow generation will continue to support its investment needs, and a credit profile appropriate for its A1 ratings."
5. The trade war, especially the last round of Trump tariffs has sent its shares crashing, so that they are now at quite an attractive valuation. As a result, the P/E based on forward 12 months earnings of 28.88X is well below the median value of 33.58 over the past year. It’s also better than the industry’s 38.37X.
6. Interestingly, Alibaba is reportedly considering a Hong Kong listing to raise $20 billion according to people with confidential knowledge of the matter. The company needs to maintain liquidity and increase investment in technology is all we are getting from the read. But considering the U.S. government’s strong stand with respect to Huawei and Hong Kong recently relaxing its listing requirements, Alibaba may be looking to raise funds that can help it pull out of the U.S.
Market watcher and former Trump chief adviser Steve Bannon’s recent comment in the South China Morning Post reads: "The next move we make is to cut off all the IPOs, unwind all the pension funds and insurance companies in the U.S. that provide capital to the Chinese Communist Party." If this is true, it could be an opportunity to make some money.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>